VASP (Ab-239) Antibody

What is VASP and what cellular functions does it regulate?

Vasodilator-stimulated phosphoprotein (VASP) belongs to the Ena/VASP family of actin-associated proteins involved in cytoskeleton remodeling and cell polarity. VASP regulates numerous cellular processes including axon guidance, lamellipodial and filopodial dynamics, platelet activation, and cell migration. At the molecular level, VASP promotes actin filament elongation by protecting the barbed end of growing actin filaments against capping and increasing actin polymerization rates in the presence of capping protein. The protein stimulates actin filament elongation specifically by facilitating the transfer of profilin-bound actin monomers onto the barbed end of growing filaments. Additionally, VASP plays a significant role in actin-based mobility of Listeria monocytogenes in host cells and regulates actin dynamics in platelets, contributing importantly to platelet aggregation regulation .

What are the key characteristics of VASP (Ab-239) antibody?

VASP (Ab-239) antibody is a rabbit polyclonal antibody specific to the peptide sequence around amino acids 236-240 (K-V-S-K-Q) derived from human VASP. The antibody is capable of detecting endogenous levels of total VASP protein across multiple species including human, mouse, and rat samples. Regarding technical specifications, the antibody is typically supplied at a concentration of 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol. For optimal preservation, storage at -20°C is recommended for long-term use, while 4°C is suitable for short-term storage. The antibody is primarily validated for Western blot applications with recommended dilutions ranging from 1:500-1:1000 .

How does VASP phosphorylation affect its function in different cell types?

VASP phosphorylation at different serine residues creates distinct functional effects. Phosphorylation at serine 239 (pS239) correlates with inhibition of F-actin bundling by VASP, unlike phosphorylation at serine 157 (pS157) which does not demonstrate this effect. This site-specific phosphorylation is particularly important in smooth muscle cells (SMCs), where pS239 mediates the effects of nitric oxide (NO) on SMC adhesion, spreading, contraction, and invasion. While S239D-VASP (phosphomimetic) SMCs and NO-treated wild-type VASP SMCs show decreased membrane protrusions, they can still form initial protrusions, suggesting that serine 239 phosphorylation is not critical for initiating cell protrusion events but rather for subsequent cytoskeletal organization. Additionally, VASP phosphorylation at S322 has been identified as a potential biomarker for aggressive invasive ductal carcinoma, demonstrating the contextual importance of different phosphorylation sites in disease states .

What are the optimal conditions for using VASP (Ab-239) antibody in Western blot applications?

For Western blot applications, VASP (Ab-239) antibody demonstrates optimal performance at dilutions ranging from 1:500-1:1000. When designing your experiment, protein extraction conditions must be optimized to preserve VASP's native state or specific phosphorylation status. For analyzing VASP from cell lysates, extracts from serum-treated 293 cells or PMA-treated C6 cells have been successfully used as positive controls. The anticipated band size for VASP is approximately 39 kDa, though phosphorylated forms may demonstrate an apparent molecular mass shift from 46 to 50 kDa by SDS-PAGE, particularly when phosphorylated at serine 157. For detection, anti-rabbit secondary antibodies conjugated with HRP work effectively. Importantly, when studying both phosphorylated and total VASP levels, consider running parallel blots or stripping and reprobing, as determining the P-VASP/VASP ratio provides more accurate assessment of phosphorylation status than absolute P-VASP levels alone .

How can I effectively design experiments to study VASP phosphorylation at different serine residues?

To effectively study site-specific VASP phosphorylation, a multi-faceted experimental approach is recommended. Begin with temporal phosphorylation analysis by stimulating cells/tissues with appropriate agonists (e.g., acetylcholine for Ser157 phosphorylation or NO donors for Ser239 phosphorylation) over various time points (5-30 minutes is typically sufficient). For visualization, use site-specific antibodies targeting individual phosphorylation sites (pS157-VASP, pS239-VASP, or pS322-VASP).

When designing controls, include both unstimulated samples and positive controls (e.g., forskolin-stimulated samples for cAMP-dependent pathways affecting Ser157). For monitoring stoichiometric changes, exploit the characteristic mobility shift from 46 to 50 kDa by SDS-PAGE that occurs with Ser157 phosphorylation. Additionally, proximity ligation assay (PLA) using probes against phospho-specific and total VASP antibodies provides powerful spatial information about phosphorylation events, with positive signals indicating target epitopes in close proximity (<40 nm) .

For functional studies, consider using phosphomimetic (S→D) or phospho-null (S→A) VASP mutants expressed in VASP-null backgrounds to isolate the effects of specific phosphorylation sites. This approach has been particularly effective in studying the role of S239 phosphorylation in smooth muscle cell contraction and cytoskeletal organization .

What immunohistochemistry protocol is recommended when using VASP antibodies on tissue samples?

For immunohistochemistry applications with VASP antibodies, the following optimized protocol is recommended based on published methodologies:

• Sample preparation: Fix tissue sections in formalin and embed in paraffin, then section at 5μm thickness.

• Deparaffinization and rehydration: Process sections through xylene and graded ethanol series.

• Antigen retrieval: For VASP epitopes, perform high-pressure antigen retrieval with 10 mM citrate buffer at pH 6.0 before immunostaining.

• Peroxidase blocking: Treat sections with 3% H₂O₂ for five minutes to reduce endogenous peroxidase activity.

• Washing and blocking: Wash with PBS containing 0.5% Tween 20, then block with protein block serum-free solution for five minutes at room temperature.

• Primary antibody incubation: Dilute antibodies in Antibody Diluent Background Reducing Solution at the following concentrations:

  • Anti-VASP: 1:2000

  • Anti-pS157-VASP: 1:25 to 1:100

  • Anti-pS239-VASP: 1:100

  • Anti-pS322-VASP: 1:1000

• Detection: For chromogenic detection, use EnVision Plus Anti-Rabbit Labelled Polymer Kit according to manufacturer's instructions. For immunofluorescence, use Alexa Fluor 488 or Alexa Fluor 568 labeled secondary antibodies at 1:500 dilution (room temperature, 1 hour), followed by DAPI counterstaining (125 μg/ml for 15 minutes).

• Mounting: Use appropriate mounting medium such as LabVision PermaFluor for fluorescence applications.

This protocol has been validated for detecting various forms of VASP in multiple tissue types and provides consistent, specific staining patterns .

How can VASP (Ab-239) antibody be used to investigate actin cytoskeleton dynamics in experimental models?

VASP (Ab-239) antibody serves as a valuable tool for investigating actin cytoskeleton dynamics by enabling visualization and quantification of VASP's role in actin filament organization. For comprehensive analysis, implement a multi-method approach combining biochemical assays with advanced imaging techniques.

Begin by establishing baseline VASP expression in your model system using Western blotting with VASP (Ab-239) antibody at 1:500-1:1000 dilution. For perturbation studies, introduce cytoskeletal disrupting agents (e.g., cytochalasin D, latrunculin B) or signaling modulators (e.g., NO donors, cAMP/cGMP pathway activators) to examine how VASP localization and phosphorylation status change in response to altered actin dynamics.

For spatial analysis, employ immunofluorescence microscopy with VASP (Ab-239) alongside F-actin staining (phalloidin) to visualize co-localization patterns, particularly at membrane protrusions, lamellipodia, and filopodia. More advanced investigation can utilize proximity ligation assays (PLA) to identify VASP interactions with other actin-regulatory proteins within a 40 nm radius, providing insight into molecular complexes forming during actin polymerization.

In cellular function studies, combine VASP antibody staining with live-cell imaging after introducing GFP-VASP or phospho-mutant constructs (S239A, S239D) to track dynamic changes in VASP localization during cell migration, adhesion, or response to extracellular stimuli. This approach has proven particularly effective in smooth muscle cells, where VASP phosphorylation status significantly impacts membrane protrusion formation and cytoskeletal organization in response to contractile stimuli .

What approaches can be used to study the relationship between VASP phosphorylation and disease states?

To investigate the relationship between VASP phosphorylation and disease states, researchers should implement a comprehensive translational approach spanning molecular, cellular, and clinical analyses:

• Clinical sample analysis: Obtain patient-derived tissues (e.g., tumor biopsies, vascular specimens) and analyze phosphorylation status at different VASP sites (S157, S239, S322) using site-specific antibodies. The phosphorylation ratio of these different sites may serve as potential biomarkers, as demonstrated in studies showing pS322-VASP association with aggressive invasive ductal carcinoma.

• Phosphorylation profiling: Develop phosphorylation panels examining multiple VASP sites simultaneously using multiplexed immunofluorescence or mass spectrometry-based phosphoproteomics to establish disease-specific phosphorylation signatures.

• Functional consequences assessment: Express phosphomimetic (S→D) or phospho-null (S→A) VASP mutants in disease-relevant cell types to determine how specific phosphorylation events affect disease-associated phenotypes (e.g., migration, invasion, adhesion). This approach has effectively demonstrated that S239 phosphorylation impacts smooth muscle contraction and might be relevant to vascular pathologies.

• Signaling pathway interrogation: Use pharmacological modulators or genetic approaches to manipulate pathways known to regulate VASP phosphorylation (PKA, PKG, AMPK) and assess how alterations in these pathways correlate with disease progression.

• In vivo models: Generate transgenic mouse models expressing phospho-mutant VASP to examine disease phenotypes in whole organisms. VASP-/- mice expressing S239A or S239D mutants have been used effectively to study smooth muscle cell functions relevant to cardiovascular disease.

The integration of these approaches has revealed that phosphorylation status not only serves as a potential biomarker but also mechanistically contributes to disease processes, as seen in cancer invasion studies and vascular smooth muscle investigations .

How does VASP phosphorylation at serine 239 specifically influence nitric oxide effects on smooth muscle cells?

VASP phosphorylation at serine 239 serves as a critical regulatory mechanism through which nitric oxide (NO) modulates smooth muscle cell (SMC) behavior. The underlying molecular mechanisms involve a sophisticated interplay between cytoskeletal organization and contractile function:

This mechanistic understanding provides insight into how NO functions as a vasodilator and suggests VASP phosphorylation as a potential therapeutic target for vascular disorders characterized by abnormal smooth muscle contractility .

How can I accurately quantify the phosphorylation status of VASP for comparative studies?

Accurate quantification of VASP phosphorylation requires standardized methodologies to control for variable expression levels and experimental variations. The recommended approach involves calculating phosphorylation ratios rather than absolute values:

• P-VASP/VASP ratio determination: For Western blot analysis, standardize all bands (VASP, P-VASP) against a loading control such as β-tubulin. Then, express the intensity of P-VASP bands in treated samples as a percentage of control samples. Finally, calculate the P-VASP/VASP ratio to accurately represent the extent of phosphorylation at specific sites. This ratio corrects for variable VASP expression levels and recovery variations caused by experimental procedures.

• Positive controls inclusion: Include appropriate positive controls in each experiment. For cGK-I-mediated VASP phosphorylation studies, use 10 ng recombinant cGK-I as a positive control. For phosphorylated VASP detection, 1 μg protein of SNP-stimulated human platelets serves as an effective positive control.

• Mobility shift analysis: When analyzing serine 157 phosphorylation, exploit the characteristic shift in apparent molecular mass from 46 to 50 kDa by SDS-PAGE. This shift provides a visual confirmation of phosphorylation status that complements antibody-based detection.

• Parallel blotting strategy: Rather than stripping and reprobing, which can lead to signal loss, prepare parallel blots from the same samples for probing with different antibodies (total VASP and site-specific phospho-VASP).

• Densitometric analysis optimization: Use linear range exposure times for all Western blots to ensure accurate densitometric quantification. Background subtraction should be performed consistently across all samples to minimize artifactual variations in signal intensity.

This comprehensive approach to VASP phosphorylation quantification has been validated in multiple experimental systems and provides reliable comparative data for statistical analysis .

What are the common challenges in detecting phosphorylated VASP and how can they be overcome?

Detecting phosphorylated VASP presents several technical challenges that can be addressed through optimized experimental approaches:

• Rapid dephosphorylation during sample preparation: Phosphorylated VASP can be rapidly dephosphorylated by endogenous phosphatases during tissue/cell processing.

  • Solution: Incorporate phosphatase inhibitors (sodium fluoride, sodium pyrophosphate, sodium orthovanadate) in all lysis buffers. Process samples rapidly at 4°C, and consider adding phosphatase inhibitors to any wash buffers used during tissue collection.

• Variable phosphorylation stoichiometry: Different phosphorylation sites may be modified at variable rates and to different extents.

  • Solution: Design time-course experiments to capture peak phosphorylation times for each site. For S157, phosphorylation typically approaches maximum by 10 minutes of stimulation with appropriate agonists.

• Antibody cross-reactivity between phosphorylation sites: Some phospho-specific antibodies may recognize multiple phosphorylated residues.

  • Solution: Validate antibody specificity using phospho-null mutants (S→A) as negative controls. For definitive site identification, consider supplementing antibody-based detection with mass spectrometry analysis.

• Tissue heterogeneity affecting phosphorylation detection: In complex tissues, cell-specific phosphorylation patterns may be obscured.

  • Solution: Complement Western blot analysis with immunohistochemistry or immunofluorescence to visualize cell-specific phosphorylation patterns. For tissues like vascular walls, consider removing specific layers (e.g., endothelium) to isolate signals from particular cell types.

• Quantification challenges with multiple phosphorylation sites: When multiple sites are phosphorylated simultaneously, band pattern interpretation becomes complex.

  • Solution: Use site-specific antibodies in parallel blots rather than sequential stripping/reprobing. For multi-site analysis, consider proximity ligation assays (PLA) that can visualize specific phosphorylation events with high spatial resolution.

By implementing these solutions, researchers can overcome common technical challenges and obtain reliable, reproducible data on VASP phosphorylation status across experimental conditions .

How can I differentiate between phospho-specific and total VASP antibodies in experimental design?

Differentiating between phospho-specific and total VASP antibodies requires careful experimental design to ensure accurate interpretation of results:

• Antibody selection strategy:

  • Total VASP antibodies typically target conserved regions of the protein that are not affected by phosphorylation status. The VASP (Ab-239) antibody recognizes the peptide sequence around amino acids 236-240 (K-V-S-K-Q).

  • Phospho-specific antibodies target the precise phosphorylation site and surrounding amino acids. For example, phospho-S239 VASP antibodies specifically recognize VASP only when serine 239 is phosphorylated.

• Validation approaches:

  • Confirm antibody specificity using phosphomimetic (S→D) or phospho-null (S→A) VASP mutants expressed in VASP-null backgrounds.

  • Test reactivity following treatment with phosphatases to demonstrate phosphorylation-dependent recognition.

  • For phospho-specific antibodies, verify signal increase following treatments known to induce site-specific phosphorylation (e.g., NO donors for S239 phosphorylation).

• Experimental controls:

  • Include positive controls for each antibody: total protein extracts for total VASP antibodies and phosphorylation-inducing treatments for phospho-specific antibodies.

  • For phospho-S239 VASP, SNP-stimulated human platelets serve as effective positive controls.

  • For total VASP detection, baseline expression in 293 cells provides a reliable reference.

• Parallel analysis approach:

  • Rather than sequential detection on the same membrane, prepare parallel blots from identical samples.

  • Alternatively, if sequential detection is necessary, thoroughly document the original signal before stripping, and verify complete stripping before reprobing.

• Multiplexed detection:

  • When available, use differentially labeled secondary antibodies to simultaneously detect total and phosphorylated VASP on the same blot.

  • For immunofluorescence applications, employ distinct fluorophores (e.g., Alexa Fluor 488 for one antibody and Alexa Fluor 568 for another) to visualize total and phosphorylated VASP in the same sample.

By implementing these approaches, researchers can clearly differentiate between total and phosphorylated VASP populations, enabling accurate assessment of phosphorylation status across experimental conditions .

How does VASP (Ab-239) antibody compare to other VASP antibodies targeting different epitopes?

VASP (Ab-239) antibody offers distinct advantages and limitations compared to other VASP antibodies targeting different epitopes:

When designing experiments requiring comprehensive VASP analysis, combining VASP (Ab-239) with phospho-specific antibodies provides the most complete picture. For example, using VASP (Ab-239) to determine total VASP levels alongside phospho-S239 VASP antibody allows calculation of the P-VASP/VASP ratio, offering a normalized measure of phosphorylation status independent of total VASP expression variability .

What are the considerations for using VASP (Ab-239) antibody in studies of neurological disorders?

When employing VASP (Ab-239) antibody in neurological disorder research, several specialized considerations must be addressed:

• Neuronal-specific expression patterns: VASP expression and function in neuronal tissues differ from peripheral tissues. In neuronal contexts, VASP localizes predominantly to growth cones and synaptic structures where it regulates axon guidance and dendritic spine formation. When designing experiments, include appropriate neuronal markers (MAP2, β-III-tubulin) to correlate VASP localization with specific neuronal compartments.

• Modified sample preparation protocols: Brain tissue requires specialized extraction procedures to preserve protein integrity and phosphorylation status:

  • Implement rapid tissue harvest with immediate flash-freezing to prevent post-mortem dephosphorylation

  • Use specialized brain tissue lysis buffers containing higher detergent concentrations to solubilize membrane-associated VASP populations

  • Consider region-specific analysis, as VASP expression and phosphorylation patterns vary across brain regions

• ApoE interactions: Recent research has identified important interactions between VASP and ApoE, particularly relevant to Alzheimer's disease models. When investigating these interactions:

  • Use siRNA approaches to modulate VASP expression in apoE3 and apoE4 neuronal models

  • Consider the effects of phospho-null mutations (VASP S239A) on ApoE-dependent processes

  • Implement affinity purification mass spectrometry with GFP-VASP constructs to identify neural-specific interaction partners

• Blood-brain barrier considerations: For in vivo studies, account for antibody penetration limitations across the blood-brain barrier by:

  • Optimizing fixation protocols for immunohistochemistry to preserve epitope accessibility while maintaining tissue architecture

  • Implementing transcardial perfusion for animal models to ensure thorough tissue fixation

• Neuroinflammation context: In neuroinflammatory conditions, VASP phosphorylation patterns may be altered by activated microglia and reactive astrocytes. Include glial markers (GFAP, Iba1) in immunofluorescence studies to distinguish between neuronal and glial VASP populations.

By addressing these specialized considerations, researchers can effectively employ VASP (Ab-239) antibody to investigate the role of VASP in neurological disorders, particularly those involving cytoskeletal dysregulation and synaptic dysfunction .

How can VASP (Ab-239) antibody be integrated into high-throughput phosphoproteomic screening approaches?

Integrating VASP (Ab-239) antibody into high-throughput phosphoproteomic screening approaches requires strategic adaptation of conventional methods to accommodate larger sample volumes while maintaining detection specificity:

• Antibody-based microarray development:

  • Immobilize VASP (Ab-239) antibody on microarray surfaces to capture total VASP from complex samples

  • Follow with detection using phospho-site-specific antibodies labeled with distinct fluorophores

  • This sandwich approach enables simultaneous quantification of multiple phosphorylation sites (S157, S239, S322) across numerous samples

  • Validate array results against conventional Western blot analysis for a subset of samples

• Multiplexed bead-based assays:

  • Conjugate VASP (Ab-239) antibody to spectrally distinct microspheres

  • Implement in flow cytometry-based platforms for simultaneous detection of multiple VASP phosphorylation states

  • Calibrate against recombinant phosphorylated VASP standards to enable absolute quantification

  • This approach has been successfully utilized for phosphoprotein analysis in platelets and could be adapted for VASP-specific applications

• Mass spectrometry integration:

  • Use VASP (Ab-239) antibody for immunoprecipitation to enrich VASP from complex samples

  • Couple with targeted mass spectrometry approaches (PRM, MRM) for site-specific phosphorylation analysis

  • Implement stable isotope-labeled peptide standards for absolute quantification of phosphorylation stoichiometry

  • This approach has been demonstrated in GFP-VASP affinity purification MS studies in neuronal models

• Automated Western blot platforms:

  • Adapt VASP (Ab-239) antibody protocols for capillary-based automated Western systems

  • Optimize antibody dilutions (typically higher concentrations than conventional Westerns)

  • Implement multiplexed detection with phospho-specific antibodies using distinct fluorophores

  • Validate reproducibility across batches using standardized positive controls

• High-content imaging adaptation:

  • Optimize VASP (Ab-239) antibody concentrations for automated immunofluorescence in multiwell formats

  • Combine with phospho-specific antibodies for ratio-based quantification at single-cell resolution

  • Implement machine learning algorithms to classify cellular phenotypes based on VASP phosphorylation patterns

  • This approach enables correlation of phosphorylation status with morphological parameters

These integrated approaches enable comprehensive phosphorylation profiling across large sample cohorts, facilitating biomarker discovery and therapeutic target identification in various disease contexts .

What emerging applications of VASP (Ab-239) antibody show promise in translational research?

Several emerging applications of VASP (Ab-239) antibody demonstrate significant potential for translational research across multiple disciplines:

• Cardiovascular disease biomarker development: VASP phosphorylation status represents a promising biomarker for endothelial dysfunction and early vascular disease. By establishing standardized protocols using VASP (Ab-239) antibody in combination with phospho-specific antibodies, researchers can develop blood-based assays quantifying the P-VASP/VASP ratio as an indicator of vascular health. This application builds on established research demonstrating that VASP phosphorylation at serine 239 reflects the integrated activity of NO-cGMP signaling pathways critical to vascular homeostasis.

• Cancer progression monitoring: The role of VASP in cell migration and invasion positions it as a potential biomarker for cancer aggressiveness. Recent findings connecting VASP phosphorylation at S322 with invasive ductal carcinoma suggest applications for VASP (Ab-239) antibody in developing tissue-based prognostic assays. By standardizing immunohistochemical protocols and establishing phosphorylation score thresholds, pathologists could implement VASP analysis into routine cancer assessment.

• Neurodegenerative disease mechanisms: The identification of interactions between VASP and apoE4, a major genetic risk factor for Alzheimer's disease, opens new avenues for investigating cytoskeletal dysregulation in neurodegeneration. VASP (Ab-239) antibody could be utilized in high-content screening approaches to identify compounds that normalize VASP phosphorylation patterns disturbed by apoE4 expression.

• Platelet function testing: VASP's critical role in platelet aggregation suggests applications for monitoring antiplatelet therapy effectiveness. Flow cytometry-based assays using VASP (Ab-239) antibody alongside phospho-specific antibodies could provide rapid assessment of platelet reactivity in patients receiving agents targeting the NO-cGMP pathway.

• Infectious disease research: VASP's involvement in Listeria monocytogenes actin-based mobility presents opportunities for therapeutic intervention in intracellular bacterial infections. High-throughput screening platforms incorporating VASP (Ab-239) antibody could identify compounds disrupting pathogen-induced cytoskeletal manipulation.

These translational applications highlight the versatility of VASP (Ab-239) antibody across multiple disease contexts and its potential to bridge fundamental research with clinical applications .

How might advances in quantitative microscopy enhance VASP phosphorylation research using VASP antibodies?

Advances in quantitative microscopy offer transformative opportunities for VASP phosphorylation research when combined with appropriate antibodies:

• Super-resolution microscopy applications: Conventional immunofluorescence has limited ability to resolve VASP localization within complex cytoskeletal structures. Emerging super-resolution techniques (STORM, PALM, SIM) enable visualization of VASP organization at nanometer scale:

  • Map precise VASP distribution at the leading edge of migrating cells

  • Visualize VASP clustering at actin filament barbed ends

  • Track phosphorylation-dependent changes in VASP nanoscale organization

• Single-molecule tracking: Advanced microscopy enables tracking of individual VASP molecules in living cells:

  • Observe real-time recruitment of VASP to growing actin filaments

  • Quantify how phosphorylation alters VASP residence time at specific cellular structures

  • Measure diffusion coefficients of phosphorylated versus non-phosphorylated VASP

• FRET-based phosphorylation sensors: Förster resonance energy transfer (FRET) biosensors incorporating VASP can provide dynamic phosphorylation readouts:

  • Design intramolecular FRET sensors where phosphorylation induces conformational changes

  • Monitor phosphorylation kinetics in response to various stimuli in real-time

  • Visualize subcellular phosphorylation patterns with high temporal resolution

• Correlative light-electron microscopy (CLEM): This approach combines fluorescence localization of VASP with ultrastructural context:

  • Precisely localize phosphorylated VASP relative to specific cytoskeletal structures

  • Correlate VASP phosphorylation with membrane topography and organelle positioning

  • Integrate immunofluorescence data with tomographic reconstructions of the cytoskeleton

• Automated high-content analysis: Computational approaches enable extraction of complex phosphorylation patterns:

  • Implement machine learning algorithms to classify cells based on VASP phosphorylation profiles

  • Correlate phosphorylation patterns with morphological parameters across thousands of cells

  • Develop phosphorylation-based phenotypic signatures for various cellular states

These advanced microscopy approaches, when combined with appropriate VASP antibodies, will enable unprecedented insights into the spatial and temporal dynamics of VASP phosphorylation and its functional consequences in cellular processes and disease states .